Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein

被引:86
作者
Wyatt, R
Desjardin, E
Olshevsky, U
Nixon, C
Binley, J
Olshevsky, V
Sodroski, J
机构
[1] HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115
[2] HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115
[3] HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115
[4] ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016
关键词
D O I
10.1128/JVI.71.12.9722-9731.1997
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human immunodeficiency virus type 1 (HIV-1) gp120 exterior envelope glycoprotein interacts with the viral receptor (CD4) and with the gp41 transmembrane envelope glycoprotein. To study the interaction of the gp120 and gp41 envelope glycoproteins, we compared the abilities of anti-gp120 monoclonal antibodies to bind soluble gp120 and a soluble glycoprotein, sgp140, that contains gp120 and gp41 exterior domains. The occlusion or alteration of a subset of gp120 epitopes on the latter molecule allowed the definition of a gp41 ''footprint'' on the gp120 antibody competition map. The occlusion of these epitopes on the sgp140 glycoprotein was decreased by the binding of soluble CD4. The gp120 epitopes implicated in the interaction with the gp41 ectodomain were disrupted by deletions of the first (C1) and fifth (C5) conserved gp120 regions. These deletions did not affect the integrity of the discontinuous binding sites for CD4 and neutralizing monoclonal antibodies. Thus, the gp41 interface on the HIV-1 gp120 glycoprotein, which elicits nonneutralizing antibodies, can be removed while retaining immunologically desirable gp120 structures.
引用
收藏
页码:9722 / 9731
页数:10
相关论文
共 91 条
[1]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[2]  
[Anonymous], SCIENCE
[3]   ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
BARRESINOUSSI, F ;
CHERMANN, JC ;
REY, F ;
NUGEYRE, MT ;
CHAMARET, S ;
GRUEST, J ;
DAUGUET, C ;
AXLERBLIN, C ;
VEZINETBRUN, F ;
ROUZIOUX, C ;
ROZENBAUM, W ;
MONTAGNIER, L .
SCIENCE, 1983, 220 (4599) :868-871
[4]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN MOLECULES CONTAINING MEMBRANE FUSION-IMPAIRING MUTATIONS IN THE V3-REGION EFFICIENTLY UNDERGO SOLUBLE CD4-STIMULATED GP120 RELEASE [J].
BERGER, EA ;
SISLER, JR ;
EARL, PL .
JOURNAL OF VIROLOGY, 1992, 66 (10) :6208-6212
[5]   ANTIGENIC IMPLICATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE QUATERNARY STRUCTURE - OLIGOMER-SPECIFIC AND OLIGOMER-SENSITIVE MONOCLONAL-ANTIBODIES [J].
BRODER, CC ;
EARL, PL ;
LONG, D ;
ABEDON, ST ;
MOSS, B ;
DOMS, RW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (24) :11699-11703
[6]  
BUGELSKI PJ, 1991, J ACQ IMMUN DEF SYND, V4, P923
[7]   THE REGION OF THE ENVELOPE GENE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESPONSIBLE FOR DETERMINATION OF CELL TROPISM [J].
CANN, AJ ;
CHURCHER, MJ ;
BOYD, M ;
OBRIEN, W ;
ZHAO, JQ ;
ZACK, J ;
CHEN, ISY .
JOURNAL OF VIROLOGY, 1992, 66 (01) :305-309
[8]   EFFECTS OF AMINO-ACID CHANGES IN THE EXTRACELLULAR DOMAIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP41 ENVELOPE GLYCOPROTEIN [J].
CAO, J ;
BERGERON, L ;
HELSETH, E ;
THALI, M ;
REPKE, H ;
SODROSKI, J .
JOURNAL OF VIROLOGY, 1993, 67 (05) :2747-2755
[9]   DESIGNING CD4 IMMUNOADHESINS FOR AIDS THERAPY [J].
CAPON, DJ ;
CHAMOW, SM ;
MORDENTI, J ;
MARSTERS, SA ;
GREGORY, T ;
MITSUYA, H ;
BYRN, RA ;
LUCAS, C ;
WURM, FM ;
GROOPMAN, JE ;
BRODER, S ;
SMITH, DH .
NATURE, 1989, 337 (6207) :525-531
[10]   VIRAL DETERMINANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 T-CELL OR MACROPHAGE TROPISM, CYTOPATHOGENICITY, AND CD4 ANTIGEN MODULATION [J].
CHENGMAYER, C ;
QUIROGA, M ;
TUNG, JW ;
DINA, D ;
LEVY, JA .
JOURNAL OF VIROLOGY, 1990, 64 (09) :4390-4398